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ABSTRACT
Many patients receiving allogeneic stem cells develop chronic graft-versus-host disease (cGVHD), which
remains as the main cause of morbidity and mortality. Although the first line of therapy is generally with
steroids, it is not well known how to manage refractory cases. Those patients are usually treated with
alternative experimental agents. Sirolimus (Rapamycin), a new immunosuppressive agent, inhibits signal
transduction and cell cycle progression after binding to FKBP12. We report a retrospective analysis with
sirolimus in transplant recipients with cGVHD refractory to previous immunosuppressive therapy. Forty-
seven patients with refractory or relapsed cGVHD were treated with the combination of sirolimus and
calcineurin inhibitors (n 33), mycophenolate (n 9), or prednisone (n 5). Thirty-eight of 47 (81%) patients
had clinical responses (complete  18, partial  20). The main toxicity was mild renal failure, particularly at
the start of therapy. Four patients who presented thrombotic microangiopathy were managed with plasma-
pheresis and the discontinuation of sirolimus and calcineurin inhibitors. Statistical analysis showed the type of
cGVHD onset and presirolimus clinical status as the main variables influencing the response to treatment. The
Kaplan-Meier estimate of survival was 57.4% at 3 years. The current study shows the efficacy and safety of
sirolimus in refractory cGVHD patients. Further investigation is warranted to elucidate the role of sirolimus
in cGVHD, and find the best combination (sirolimus  calcineurin inhibitors versus others) for therapeutic
use.
© 2007 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
Over 60% of patients transplanted with allogeneic
tem cells eventually develop chronic graft-versus-
ost disease (cGVHD), which causes profound immu-
osuppression. In fact, most cGVHD deaths are at-
ributable to infection in patients otherwise cured
rom their disease [1,2]. First-line therapy in standard-
isk patients with clinical extensive cGVHD consists
f cyclosporine (CSP) or prednisone, and it is not
lear whether the combination of both is superior to ponotherapy [3]. However, among patients who are
onsidered high risk, especially those with platelet
ounts 100  109/L, CSP plus prednisone has been
eported to show better survival than that observed
ith prednisone alone [4].
Patients who fail to respond to standard immu-
osuppressive regimens may be treated with alter-
ative agents with different degrees of success [5-9].
irolimus (Rapamycin), a relatively new immunosup-
ressive agent, binds to the FK506-binding protein
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M. Jurado et al.702FKBP) 12 and interacts with the mammalian target
f rapamycin (mTOR). The Sirolimus-FKBP-
TOR complex inhibits signal transduction and
ell cycle progression by blocking the ability of T
ells to proliferate in response to interleukin-2 [10].
irolimus has a synergistic effect with CSP or ta-
rolimus, demonstrated not only in the experimen-
al setting [11] but also in solid-organ transplanta-
ion, leading to an improvement of allograft survival
12,13]. In addition to its immunosuppressive activ-
ty, other properties such as antiviral and antineo-
lastic effects are recognized for sirolimus [14-16].
n the setting of stem cell transplantation, sirolimus
as been used both as prophylaxis and salvage ther-
py for acute GVHD (aGVHD) and cGVHD, with
ncouraging results [17-20]. Here we present a ret-
ospective evaluation of the use of sirolimus in
ransplant recipients with refractory and relapsed
GVHD.
ATERIALS AND METHODS
tudy Design
Between February 2002 and July 2005, 47 patients
ith treatment-refractory or relapsed cGVHD were
reated with sirolimus as salvage therapy in 8 hospitals
n Spain. Characteristics of the patients, their previous
able 1. Patient Characteristics
Variable N  47 %
ge 41 (19-63)
ex
Male 17 36
Female 30 64
onor type
Matched related 38 81
Matched unrelated 9 19
tem cells source
Cord blood 1 2
Bone marrow 5 11
Peripheral blood 41 87
ntensity of conditioning
Myeloablative 28 60
Reduced intensity 19 40
ndication for SCT
CML 13 28
Lymphomas 14 30
AML 9 19
ALL 3 6
CLL 2 4
Myeloma 1 2
CMML 1 2
MDS 2 4
Others 2 4
CT indicates stem cell transplantation; CML, chronic myeloge-
nous leukemia; AML, acute myelogenous leukemia; ALL, acute
lymphoid leukemia; CLL, chronic lymphoid leukemia; CMML,
chronic myelomonocytic leukemia; MDS, myelodysplastic syn-
drome.
Sreatment and cGVHD proﬁles are shown in Tables 1
nd 2. Sirolimus was used in combination with other
mmunosuppressive agents as indicated in Table 3.
he dosage of sirolimus was 2 mg once a day orally to
aintain a level of 5-10 ng/mL. CSP and tacrolimus
ere given twice a day and adjusted to maintain
rough levels of 150-250 and 5-10 ng/mL, respec-
ively. The dosage of mycophenolate mofetil was 1 g
wice a day. Steroids were given at 1 mg per kg a day
nd were tapered as soon as clinically possible. One
atient received azathioprine at a dose of 1 mg per
g a day, in combination with sirolimus and FK-
06. Sirolimus was administered in all cases under
ompassionate use, and patients had signed in-
ormed consent. Patients receiving any calcineurin
nhibitors along with sirolimus had renal function
onitored at weekly intervals, and dose adjustments
ere made until levels remained stable within the
herapeutic range. Because patients with cGVHD
re immunodeﬁcient and have a high risk of infec-
ions, antimicrobial prophylaxis involving tri-
ethoprim-sulfamethoxazole, acyclovir, and ﬂu-
onazole was used according to the protocols of
hysicians from each center. Patients who devel-
able 2. Chronic GVHD Proﬁle
Variable N  47 %
GVHD onset type
De novo 14 30
Quiescent 19 40
Progressive 14 30
GVHD state presirolimus
Relapse 8 17
Partial response 13 28
Refractory/progressive 26 55
cleroderma 17 36
latelets <100 x 109/L 19 40
rgans involved
One 3 6
Two 18 38
Three 18 38
Four or more 8 17
umber of prior immunosuppressive lines
One 12 25
Two 16 34
Three 13 28
Four or more 6 13
VHD indicates graft versus host disease; cGVHD, chronic graft
versus host disease.
able 3. Regimens Containing Sirolimus Used
Variable N  47 %
irolimus  CSP 21 45
irolimus  CSP  mycophenolate 4 8
irolimus  tacrolimus 7 15
irolimus  tacrolimus  azathioprine 1 2
irolimus  mycophenolate 9 19
irolimus  prednisone 5 11
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Sirolimus as Part of Immunosuppressive Therapy 703ped hyperlipidemia while taking sirolimus were
ontrolled with 3-hydroxy-3-methylglutaryl/coen-
yme A inhibitors.
Complete response (CR) was deﬁned as no evi-
ence of GVHD affecting any organ or system. Partial
esponse (PR) was deﬁned as improvement in 1 or
ore involved organs, without evidence of progres-
ion in any involved organ. No response or failure was
eﬁned as no improvement over 2 months in 1 or
ore involved organs, or progression of cGVHD on
herapy. Patients who were treated with sirolimus for
2 weeks were considered unevaluable for response.
Because this study enrolled patients from different
panish hospitals where sirolimus was given under
lightly different protocols according to the investiga-
ors’ priorities, treatment varied somewhat. Here we
eport the main endpoint, efﬁcacy of therapy with
irolimus in this heterogeneous group, as well as clin-
cal variables, which could have inﬂuenced outcome.
e also describe the side effects of sirolimus.
tatistical Analysis
A descriptive analysis of variables was performed.
o study the variables related to the success of treat-
ent, a chi-squared test or Fisher’s exact test (in the
ase of small samples) was applied when the indepen-
ent variable was quantitative, and the Mann Whitney
-test for qualitative variables.
The Kaplan-Meier method was used to estimate
he probability of survival. Differences were compared
sing the Log-Rank test. The estimation of risks for
he quantitative variables of the study was done with
ox regression.
The statistical analysis was carried out using ver-
ion 14.0 of the SPSS statistical package.
ESULTS
atient Characteristics
As shown in Table 2, 26 patients (55%) were
efractory to or showed progression with previous
mmunosuppressive therapy, whereas 45% had recur-
ent cGVHD following initial responses. A group
ith special features in terms of prognosis is consti-
uted by those who had scleroderma (36%) or platelet
ounts 100  109/L (40%).
esponse to Therapy and Survival
Among 47 patients, 38 (81%) had clinical re-
ponses to sirolimus: CR in 18, and PR in 20 patients.
ix patients failed to respond (median time to failure
6 days) and 3 were unevaluable for response (2 be-
ause of early death, and 1 who had the drug discon-
inued because of toxicity). Forty-four patients who
eceived sirolimus for 2 weeks were included for
nivariate analysis. The clinical response rate was sig- ciﬁcantly lower among patients with refractory
GVHD state presirolimus as well as in those with the
rogressive onset type of cGVHD compared to de
ovo and quiescent groups. The presence of sclero-
erma, platelet counts 100  109/L and type of
mmunosuppressive combination (preceding siroli-
us) had no inﬂuence on the clinical response rate
Table 4).
The duration of therapy for the whole group was
.2 to 33.5 (median 11.2) months, the time of expo-
ure to sirolimus being longer for patients who
chieved only PR (14.3 months) than for those who
chieved CR (12.8 months). Thirty-four of the 47
atients remain alive, 16 of them still on immunosup-
ressive therapy—8 in CR and 8 in PR—at 3 to 30
onths (median 9.9) after initiating therapy. Thirteen
atients died from their underlying disease (n  2),
ulmonary hemorrhage (n  1), fungal infections
n  2), or refractory cGVHD  infections (n  8).
With a follow-up of 0.5 to 44.5 (median 18.8)
onths, projected overall survival (OS) at 3 years was
7.4 % (Figure 1). Survival was signiﬁcantly lower
mong patients with platelet counts 100  109/L
nd among those with progressive onset cGVHD, but
o signiﬁcant difference was seen by type of immuno-
uppressive combination used (Figures 2-4).
The main toxicity was mild renal function impair-
ent in 14 patients, 3 of them associated with throm-
otic microangiopathy (TMA). The level of creatinine
anged from 1.4 to 2.0 mg/dL in 7 patients and from
.1 to 2.7 in the other 7 patients, and occurred par-
icularly at the start of therapy; reinforcement of oral
ntake hydration and dose reduction of the calcineurin
nhibitors allowed continuation of therapy in most
atients. Regarding the level of immunosuppressive
gents, in 4 patients, 1 of them having TMA, siroli-
us, and/or CSP were out of range. Two patients did
able 4. Univariate Analysis
Variable Response Failure p
GVHD type
De novo 100 0 <.001
Quiescent 100 0
Progressive 65 35
cleroderma
Yes 94 6 .38
No 81 19
latelets <100 x 109/L
Yes 76 24 .18
No 93 7
mmunosuppressive combination
Sirolimus calcineurin inhibitors 86 14 1
Sirolimus others 92 8
GVHD state presirolimus
Relapse 100 0 <.001
Partial response 92 8
Refractory/progressive 78 22GVHD indicates chronic graft versus host disease.
n
a
t
m
s
t
(
m
r
s
s
e
D
v
h
c
i
e
t
a
c
c
t
c
n
m
o
t
G
n
c
F
M. Jurado et al.704ot have sirolimus or calcineurin inhibitor levels avail-
ble previous to the event, and 8 patients were on
herapeutic levels. Renal impairment was somewhat
ore frequent in the group of patients receiving
irolimus plus calcineurin inhibitors (33%) compared
o sirolimus plus other immunosuppressive agents
7%) (p  .12), although these 3 patients received
ycophenolate. Four patients developed TMA, which
esolved after plasmapheresis and discontinuation of
irolimus and calcineurin inhibitors; in 3 patients
irolimus was resumed without problems. Other side
ffects are shown in Table 5.
ISCUSSION
Several factors have contributed to improved sur-
ival of transplant patients, with the result that a
igher proportion of patients is at risk of developing
GVHD: the use of conditioning regimens of reduced
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Figure 1. Overall survival since the initiation of sirolimus.
Months
P = 0.015
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0.0 nFigure 2. Overall survival according to number of platelets.ntensity allows transplants among older patients,
arly mortality is reduced through diagnostic and
herapeutic advances, and peripheral blood precursors
re frequently used as a source of stem cells that may
onvey a higher risk of cGVHD. The pathogenesis,
linical presentation, and histology of GVHD [21],
he graft-versus-leukemia effect [22], and long-term
omplications (neoplasias, disturbances of growth and
utrition, etc.) [23] are well described; however, opti-
um therapy has not been deﬁned.
Therapy may vary in intensity dependent upon the
rgans affected or known risk factors in a given pa-
ient. In this respect the recent development of a new
VHD classiﬁcation [24] and a model for the prog-
osis of cGVHD can help researchers to develop
linical trials for different patient groups [25]. Another
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igure 4. Overall survival according to immunosuppressive combi-
Figure 3. Overall survival according to onset proﬁle of cGVHD.ation used.
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Sirolimus as Part of Immunosuppressive Therapy 705mportant aspect to clarify is the time required to
ontrol GVHD, which may be prolonged in patients
resenting with certain risk factors [26].
Patients with cGVHD unresponsive to initial
herapy (generally with steroids) can be treated with
everal immunosuppressive agents with variable re-
ults. Among them, sirolimus has proved effective in
he setting of prophylaxis and therapy, a notion sup-
orted by the present results, which show a response
ate of 81%. Other reports likewise show beneﬁcial
ffects of therapy with sirolimus in the refractory
GVHD setting. Among 35 patients with “resistant”
GVHD treated at the MD Anderson Cancer Center,
2 (63%) responded to sirolimus and tacrolimus [19].
imilar ﬁndings were described by Johnston et al. [20]
n 19 patients who received sirolimus, calcineurin in-
ibitors, and prednisone as salvage therapy for
GVHD: 15 of 16 evaluable patients had clinical re-
ponses. Phase I/II trials as rescue therapy for
GVHD using mycophenolate mofetil, TNF- antag-
nists, thalidomide, etretinate, and extracorporeal
hotopheresis [5-9], among other agents, have been
xplored with a very wide range of clinical response.
lthough patients with generalized scleroderma often
o not respsond to therapy and have a poor prognosis
27], several such patients showed good responses in
he present series. Couriel et al. [19] also made this
bservation, leading them to hypothesize that this
ight result from the antiproliferative effect of siroli-
us [28]. On the other hand, thrombocytopenia and
rogressive onset cGVHD are recognized as indepen-
ent risk factors for nonrelapse mortality (NRM);
oth these variables signiﬁcantly affected OS in our
eries as well, although clinical responses were ob-
erved.
In patients in the present study, the anti-GVHD
ffect of sirolimus was achieved in combination with
orticoids and mycophenolate, as well as with cal-
ineurin inhibitors. Such synergy makes it easier to
ecide on therapy in view of the patient=s clinical
istory (ie, previous toxicity to a given immunosup-
ressive agent).
Sirolimus increases the bioavailability of CSP in
lood, thereby increasing the risk of renal toxicity
13], so that it is recommended to decrease the dose of
able 5. Toxicity
Variable No. of Patients %
enal 14 30
MA 4 8
yperlipidemia 19 40
yelotoxicity 12 25
cne 9 19
ancreatitis 1 2
MA indicates thrombotic microangiopathy.SP when sirolimus is started and monitor closely forhe ﬁrst 3-4 weeks. TMA has also been reported in
ther series [17-20]. Although the effectiveness of
lasmapheresis is controversial in the control of TMA
29], Couriel et al. [19] showed that the procedure was
mployed in the management of this complication in
ddition to the discontinuation of tacrolimus; how-
ver, Cutler et al. [17] managed those patients by
iscontinuing tacrolimus and withholding sirolimus
ntil renal function improved. In our study, 4 pa-
ients developed TMA, and in 1 of those patients,
lasmapheresis had to be resumed because signs of
orsening of microangiopathic hemolysis occurred.
n any case, the resolution of all of our cases would
ndicate that TMA associated to sirolimus has a
avorable evolution [30].
So far, no trial has examined treatment of refrac-
ory cGVHD in a randomized fashion, and thus, pro-
pective data are not available. The present report
escribes a retrospective analysis, which suggests that
irolimus is an effective immunosuppressive agent for
he control of cGVHD, with an acceptable safety
roﬁle. Based on these preliminary results, further
nvestigation is warranted to better deﬁne the role
f sirolimus in cGVHD therapy, and determine
ptimal combinations with sirolimus for usage in
linical trials [31].
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